News 16.10.2024 Zurich, Switzerland - 14.10.2024 Neurimmune today announced that the U.S. Food and Drug Administration (FDA) has granted Alexion, AstraZeneca Rare Disease Fast Track designation for the development of ALXN2220 (formerly NI006) for the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM). ATTR-CM is a systemic, progressive and life-threatening disease caused by the deposition of...
News 15.10.2024 October 14, 2024 - Zurich, Switzerland InSphero, the global leader in 3D cell culture technology, and scientists from the U.S. Food and Drug Administration’s (FDA) National Center for Toxicological Research (NCTR) have published the largest-ever benchmarking study on liver toxicity using 3D InSight™ Human Liver Microtissues. The study tested the hepatotoxicity of 152 FDA-approved drugs,...
News 14.10.2024 SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of...
News 11.10.2024 Securecell is introducing a series of innovative high-throughput solutions to transform the way bioprocess development is done. These solutions are designed to address inefficiencies in traditional workflows by providing a high degree of automation and integration. The centerpiece of Securecell’s innovation is the Integra1 64 2, a fully automated end-to-end bioprocess development...
News 10.10.2024 Somagenetix AG, a pioneering biotech company dedicated to revolutionizing gene therapy for phagocyte disorders, announced today the initial closing of its Series A financing round, raising CHF 10 million. The round was led by Vi Partners, renowned venture capital firm specialized in life sciences and technology investments. Among others, existing...